On the other hand, idebenone, a compound recently approved for treatment of Leber's hereditary optic neuropathy (LHON) disease, increases intracellular ATP production and decreases lactate levels in MELAS cybrid cells in a NQO1-dependent manner (11). This evidence concerns the gene NQO1 and Leber hereditary optic neuropathy.